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Background
After the availability of combined antiretroviral therapy
(cART), we quantified the consequences on the general
morbidity rates, and HIV-related hospitalization rates, in
the period 1992-2008.
Methods
HIV-associated hospitalizations were assessed according
to three different periods of time: before cART intro-
duction (1992-1995), immediately after first cART avail-
ability (1996-1998), and the last one, referred to the
fully established cART era (1999-2008).
Results
During the three examined periods, an undetectable vire-
mia was never detected in any patient in the pre-cART
era, in 21% of cases in the first years of cART, and in 41%
of patients in the last years of cART (p < .0001). In paral-
lel, the mean CD4+ T-lymphocyte count in the three
study groups tested 27.2 ± 11.3 cells/μL, 39.3 ± 14.6 cells/
μL, and 89.6 ± 38.2 cells/μL, respectively (p < .001). Dur-
ing time, an increased frequency of hospitalization of het-
erosexual and female patients occurred, while the
frequenct of IVDA had a significant drop (from 69% in the
pre-cART period, to 57% during initial cART era, to 39%
at the time of consolidated cART era; p < .0001). The
patients with a prior diagnosis of full-blown AIDS repre-
sented 86%, 57%, and 33%, respectively (p < .0001), while
hospitalized inpatients who experienced a diagnosis of
AIDS concurrently with the first detection of HIV infec-
tion (the so-called “AIDS presenters”), showed an evident
temporal increase (11%, 21%, and 39%, respectively;
p < .0001). Among concurrent illnesses, a huge rise of
chronic liver diseases was registered from the pre-cART
time (18%), to the first years of cART availability (29%), to
the current time of advanced cART (48%) (p <. 0 0 1 ) ,w h i l e
an increased mortality due to hematological and solid
malignancies also occurred, although at a lesser extent
(8.2%, 11.7%, and 17.8% respectively; p <. 0 0 1 ) .
Discussion
The introduction of cART profoundly acted on the gen-
eral morbidity for HIV infection and AIDS, although the
epidemiological-clinical-laboratory scenario significantly
changed over time. These modifications need a careful
monitoring, in order to ensure a timely diagnostic and
clinical disease recognition by all involved health care-
givers who face HIV-infected patients, and to plan an
adequate allocation of available resources, funding,
structures, and dedicated personnel.
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